Identifying neoantigens involves a combination of genomic and proteomic techniques. First, next-generation sequencing (NGS) is used to identify mutations within the tumor genome. Bioinformatics tools then predict which mutations will result in neoantigen formation. Following this, mass spectrometry can be employed to validate the presence of these predicted neoantigens on the surface of cancer cells.
